臨床試驗

Histotripsy for Ablation of Liver Tumours in Asia

NCT：NCT07428356 · RECRUITING

NCT IDNCT07428356

狀態RECRUITING

開始日期2025-11-07

完成時間2029-05-07

SponsorNational Cancer Centre, Singapore (OTHER)

First posted2026-02-23

Last updated2026-10-08

簡要摘要

The HALT study aims to evaluate histotripsy in an Asian population for both primary (HCC, CCA) and secondary liver malignancies with liver-limited or oligoprogressive disease. In addition to safety and local control, the study incorporates translational endpoints including immune profiling (PBMCs, cytokines), microbiome shifts, and optional tumour biopsies. This trial will provide critical data on the feasibility, tolerability, and biological impact of histotripsy in a region with the highest burden of liver cancer.

官方來源

在 ClinicalTrials.gov 上查看 →

資料來自 ClinicalTrials.gov API。最新狀態請參閱官方紀錄。